The global dried blood spot collection cards market was valued at USD 350.6 million in 2021 and it is predicted to surpass around USD 517.83 million by 2030 with a CAGR of 4.43% from 2022 to 2030.
Report Highlights
Dried blood spot (DBS) collection cards are used to diagnose infectious diseases, particularly in resource-constrained areas, or to screen newborns for inherited metabolic problems, with a range of novel and innovative DBS uses only lately emerging.
Growing research studies for DBS testing and its advantages for diagnostic purposes are expected to fuel the market growth during the forecast period. In addition, the WHO recently recommended dried blood spot collection cards for diagnosis of HIV and hepatitis B & C due to the benefits of DBS in collecting blood and transport.
Moreover, dried blood spot collection cards have been used in a variety of toxicology applications, including toxicokinetics, epidemiological, environmental, and forensic toxicology. Dried blood spot collection cards are anticipated to be used as a sample preparation approach in forensic toxicology, and they can cost-effectively retain evidence for closed cases. Screening procedures as well as follow-up of markers of clinical or forensic interest are further toxicological applications where these cards may be progressively utilized.
Developing economies in Africa and Asia have the highest prevalence of rabies. The detection and surveillance of such diseases are hampered by the absence of clinical laboratories. Through dried blood spot collection cards, rabies can be diagnosed with limited resources. As per the data published by the Australian Trade and Investment Commission, Australia has become home to a thriving network of more than 470 biotechnology companies. A high number of established biotechnology and pharmaceutical players and extensive R&D initiatives being undertaken by them are expected to create a high need for DBS testing for therapeutic drug monitoring applications.
Various international organizations such as the U.S. Food and Drug Administration and the World Health Organization acknowledge the role of DBS cards in this pandemic. For instance, In June 2021, Symbiotic, Inc. was granted EUA by the FDA for a COVID-19 self-collect antibody test. This test can be conducted using ELISA with DBS for detecting COVID-19 antibodies in individuals aged 18 years and older, with collecting the sample in children aged 5 years and older by an adult.
The increase in the adoption of dried blood spot collection cards for therapeutic drug monitoring is a major factor expected to boost market growth in the near future. For instance, in July 2022, a study was conducted by researchers from the University of Washington and Med Biotech Laboratories to assess the feasibility of at-home dried blood spot collection along with PCR as a technique for malaria research. The study is anticipated to impact the therapeutic drug and vaccine studies for malaria. Researchers concluded that at-home dried blood spot collection cards for PCR are acceptable, robust, and feasible techniques.
On the other hand, it has been observed that dried blood spot collection cards are susceptible to cross-contamination or contamination by users, the environment, the equipment, and other collection cards during sample processing. The majority of these concerns can be mitigated by proper care and handling. Prolonged air drying of the conventional dried blood spot collection cards and contamination between samples during blood collection are some major causes of a high proportion of reactive samples.
Scope of The Report
Report Coverage | Details |
Market Size in 2021 | USD 350.6 million |
Revenue Forecast by 2030 | USD 350.6 million |
Growth rate from 2022 to 2030 | CAGR of 4.43% |
Base Year | 2021 |
Forecast Period | 2022 to 2030 |
Segmentation | Application, card type, region |
Companies Covered |
QIAGEN; Perkinelmer; Roche; Shimadzu Corporation; Ahlstrom-Munksjö; Pall Corporation; Eastern Business Forms, Inc.; Archimed Life Science Gmbh; Centogene N.V. |
Application Insights
The New Born Screening (NBS) segment dominated the market with a revenue share of over 20.3% in 2021. Increasing newborn screening is considered to be a significant growth factor in this market. For instance, according to the National Organization for Rare Disorders, it is estimated that around 4 million infants were screened in the U.S. in 2021 through drops of blood from the heel of the newborn prior to discharge from a hospital or birth center since the prevalence rate of certain metabolic errors, endocrinopathies, and hearing loss is high and can significantly contribute to morbidity.
Similarly, in May 2022, NHS England updated the guidance newborn blood spot (NBS) screening service for cystic fibrosis (CF) in the U.K. The guidance is considered a reference handbook for labs. The standard protocol includes IRT analysis based on an initial dried blood sample.
Similarly, the increasing use of dried blood spot collection card applications, such as forensic toxicology applications, compelled various players to innovate an efficient and cost-effective process. In research conducted by Simões et al. in August 2021, dried blood spot collection cards proved to be useful in detecting illicit drugs. The use of these cards also facilitates increased sample stability, allowing samples to be stored for a longer duration, thereby creating a safer work environment for analysts and sample collectors, as only a small sample volume is a requirement.
Card Type Insights
Whatman 903 held the largest revenue share of over 30.4% in 2021 as it is efficient and safe for sample identification, collection, and transport. Whatman paper is a specialized type of filter paper used extensively in qualitative analysis. The filter paper contains cellulose fibers and is manufactured using high-quality cotton linters. Thus, Whatman filter papers contain a higher proportion of alpha-cellulose, giving it consistency and quality. Growing usage of the Whatman card type in various research studies is another major factor expected to significantly impact market growth in the near future.
For instance, in June 2022, a group of researchers from the Division of Vector-Borne Diseases, Fort Collins, conducted a study to assess the Whatman FTA cards use in molecular diagnosis for detecting Yellow fever virus (YFV). The study conducted that the card can be easy to use and cost-effective in molecular diagnosis of yellow fever. Additionally, it enables the clinician to preserve viral RNA without a cold chain.
Furthermore, an increase in the utilization of Ahlstrom cards in various research studies focused on the diagnosis of diseases and other clinical applications is another major factor expected to propel the market growth during the forecast period. In March 2020, a research study published in Frontiers in Microbiology aimed at using dried blood spot tests for therapeutic monitoring and diagnosis of viral hepatitis B & C and HIV.
Regional Insights
North America dominated the market and held a revenue share of over 35.06% in 2021. The region is likely to continue a similar trend over the projected period. This growth can be attributed to the acceleration in government initiatives for newborn screening tests along with the growing research to expand the utility of DBS collection cards in various applications.
In the U.S., every baby born is required to be screened as a part of standard medical procedures, although the cost of newborn screening tests varies from state to state as each state's finance allocation is different. The screening expenses are reimbursed by health insurance or other programs. Hence, irrespective of healthcare insurance status, babies will receive the screening.
The Asia Pacific market is expected to register the fastest CAGR of 5.09% during the projected period. The key growth factors in the market are the presence of a large target population in countries, such as India, China, Japan, and South Korea. In addition, the growing adoption of innovative laboratory techniques and procedures such as dried blood spot collection cards for faster investigation and diagnosis of infectious and chronic disorders is one of the key factors driving the regional market.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Dried Blood Spot Collection Cards Market
5.1. COVID-19 Landscape: Dried Blood Spot Collection Cards Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Dried Blood Spot Collection Cards Market, By Application
8.1. Dried Blood Spot Collection Cards Market, by Application, 2022-2030
8.1.1. New Born Screening (NBS)
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Infectious Disease Testing
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Therapeutic Drug Monitoring
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Forensics
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. CRO/Research
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. Other Applications
8.1.6.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Dried Blood Spot Collection Cards Market, By Card Type
9.1. Dried Blood Spot Collection Cards Market, by Card Type, 2022-2030
9.1.1. Whatman 903
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Ahlstrom 226
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. FTA
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Dried Blood Spot Collection Cards Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Application (2017-2030)
10.1.2. Market Revenue and Forecast, by Card Type (2017-2030)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Application (2017-2030)
10.1.3.2. Market Revenue and Forecast, by Card Type (2017-2030)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Application (2017-2030)
10.1.4.2. Market Revenue and Forecast, by Card Type (2017-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Application (2017-2030)
10.2.2. Market Revenue and Forecast, by Card Type (2017-2030)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Application (2017-2030)
10.2.3.2. Market Revenue and Forecast, by Card Type (2017-2030)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Application (2017-2030)
10.2.4.2. Market Revenue and Forecast, by Card Type (2017-2030)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Application (2017-2030)
10.2.5.2. Market Revenue and Forecast, by Card Type (2017-2030)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Application (2017-2030)
10.2.6.2. Market Revenue and Forecast, by Card Type (2017-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Application (2017-2030)
10.3.2. Market Revenue and Forecast, by Card Type (2017-2030)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Application (2017-2030)
10.3.3.2. Market Revenue and Forecast, by Card Type (2017-2030)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Application (2017-2030)
10.3.4.2. Market Revenue and Forecast, by Card Type (2017-2030)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Application (2017-2030)
10.3.5.2. Market Revenue and Forecast, by Card Type (2017-2030)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Application (2017-2030)
10.3.6.2. Market Revenue and Forecast, by Card Type (2017-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Application (2017-2030)
10.4.2. Market Revenue and Forecast, by Card Type (2017-2030)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Application (2017-2030)
10.4.3.2. Market Revenue and Forecast, by Card Type (2017-2030)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Application (2017-2030)
10.4.4.2. Market Revenue and Forecast, by Card Type (2017-2030)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Application (2017-2030)
10.4.5.2. Market Revenue and Forecast, by Card Type (2017-2030)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Application (2017-2030)
10.4.6.2. Market Revenue and Forecast, by Card Type (2017-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Application (2017-2030)
10.5.2. Market Revenue and Forecast, by Card Type (2017-2030)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Application (2017-2030)
10.5.3.2. Market Revenue and Forecast, by Card Type (2017-2030)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Application (2017-2030)
10.5.4.2. Market Revenue and Forecast, by Card Type (2017-2030)
Chapter 11. Company Profiles
11.1. QIAGEN
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Perkinelmer
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Roche
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Shimadzu Corporation
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. LTE Scientific
11.5. Ahlstrom-Munksjö
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Pall Corporation
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Eastern Business Forms, Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Archimed Life Science GmbH
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Centogene N.V.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms